Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18735142 | 0.87 | KMT2A (0.39) | L3MBTL1KMT2APOLBMGAMGAA | |
| SCHEMBL18734967 | 0.86 | — | — | |
| SCHEMBL18735335 | 0.85 | L3MBTL1 (0.47) | L3MBTL1KMT2APOLBMGAMGAA | |
| SCHEMBL18734956 | 0.84 | MGAM (0.32) | MGAMGAASIMGAM2 | |
| SCHEMBL18734935 | 0.80 | KMT2A (0.32) | L3MBTL1KMT2APOLB | |
| SCHEMBL18734952 | 0.79 | MGAM (0.33) | L3MBTL1KMT2APOLBMGAMGAA | |
| SCHEMBL18735109 | 0.77 | CYP2C9 (0.34) | KMT2ACYP2C9 | |
| SCHEMBL18735399 | 0.77 | CYP2C9 (0.34) | KMT2ACYP2C9 | |
| SCHEMBL18735186 | 0.76 | CYP2C9 (0.30) | CYP2C9 | |
| SCHEMBL18735329 | 0.76 | L3MBTL1 (0.40) | L3MBTL1KMT2APOLBCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017060400-A1 | PROTECTED CARBOXYLIC ACID-BASED METABOLITES FOR THE TREATMENT OF DISESASES RELATED TO MITOCHONDRIAL DYSFUNCTIONS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-04-13 | — | — | WO | disclosed |